Physician profile
Danielle H Sutton
NPI 1598001869
$784.60
in general payments reported to CMS, 2019-2025
12 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97.24 · 2022: $160 · 2023: $231 · 2024: $156 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $132.95 | 2021-2023 | Auryxia |
| Vifor Pharma, INC. | $112.24 | 2021-2025 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.94 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $101.07 | 2021-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $77.41 | 2022-2023 | Korsuva |
| Novartis Pharmaceuticals Corporation | $63.34 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $53.39 | 2023-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $35.45 | 2022 | |
| Amgen INC. | $34.04 | 2024 | Krystexxa |
| Ardelyx, INC. | $24.46 | 2024 | Xphozah 30 Mg |
| Glaxosmithkline, LLC. | $23.25 | 2023 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $19.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.